The National Health Surveillance Agency (Anvisa) announced the voluntary recall of radiopharmaceutical batches, as disclosed in an official statement.
Voluntary recall is a preventive measure adopted when potential issues related to quality, safety, or efficacy of medicines marketed in Brazil are identified. Anvisa works closely with marketing authorization holders to ensure that medications made available to the population meet the most rigorous quality and safety standards.
Radiopharmaceuticals are medicines containing radioactive substances used in diagnostic and therapeutic procedures. These products require continuous monitoring and strict quality control throughout their entire distribution and use chain.
The agency reaffirms its commitment to post-marketing surveillance of medicines, constantly monitoring the safety of all pharmaceutical products available in the Brazilian market. Any healthcare professional or citizen who identifies problems related to medicines may report them to Anvisa through official notification channels.
Further details regarding this recall, including specific affected batches and procedures for product return, can be obtained directly from Anvisa's official statement or by contacting authorized distributors of the medication.
